Nabavizadeh S H, Janfeshan S, Karimi M H, Eidi A, Yaghobi R, Afshari A, Geramizadeh B, Malek-Hosseini S A, Kafilzadeh F
Department of Pediatrics, Yasuj University of Medical Sciences, Yasuj, Iran.
Department of Biology, Faculty of Basic Science, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Int J Organ Transplant Med. 2018;9(2):68-74. Epub 2018 May 1.
Liver function indices and anti-viral immune regulatory markers can both improve graft outcomes, which lead to better post-transplantation management and increase the possibility of surveillance in liver transplant recipients with chronic hepatitis B virus (HBV) infection.
To determine the association between the interferon regulatory factor 1 (IRF1) mRNA levels and liver enzymes in HBV-infected liver transplant recipients with and without experience of rejection.
A total of 46 chronic HBV-infected patients who had undergone liver transplant surgery was divided into 2 groups of recipients "with rejection" and "without rejection.". Blood samples were collected form each patient on days 1, 4, and 7 post-transplantation. A SYBER GREEN real-time PCR was used to evaluate the expression level of in liver recipients. Liver enzyme activities were also measured in all patients.
The expression of in the patients with rejection was up-regulated at all 3 follow-up days compared with those without rejection. The serum levels of ALT and AST were more than normal levels at 3 follow-up times in both study groups. Significant differences were found in gene expression levels and also serum ALT levels between those with and without rejection after 7 days post-transplantation.
The expression and serum ALT levels were increased significantly in patient with rejection compared to those without rejection. IRF1, an inflammatory factor, may also intensify induction of inflammatory pathways in engrafted liver and promote liver inflammation and injuries leading to liver enzymes elevation in patients with graft rejection.
肝功能指标和抗病毒免疫调节标志物均能改善移植结局,这有助于优化慢性乙型肝炎病毒(HBV)感染肝移植受者的移植后管理并增加监测可能性。
确定在有或无排斥反应经历的HBV感染肝移植受者中,干扰素调节因子1(IRF1)mRNA水平与肝酶之间的关联。
将46例接受肝移植手术的慢性HBV感染患者分为“有排斥反应”和“无排斥反应”两组受者。在移植后第1、4和7天采集每位患者的血样。采用SYBER GREEN实时荧光定量PCR法评估肝移植受者中IRF1的表达水平。同时检测所有患者的肝酶活性。
与无排斥反应的患者相比,有排斥反应的患者在所有3个随访日的IRF1表达均上调。两个研究组在3次随访时血清ALT和AST水平均高于正常水平。移植后7天,有排斥反应和无排斥反应的患者在IRF1基因表达水平以及血清ALT水平方面存在显著差异。
与无排斥反应的患者相比,有排斥反应的患者IRF1表达和血清ALT水平显著升高。炎症因子IRF1可能还会增强移植肝中炎症途径的诱导,促进肝脏炎症和损伤,导致移植排斥患者肝酶升高。